GHK-Cu (Copper Peptide): Structure, Mechanism and the Published Research

GHK-Cu is one of the most extensively documented small peptides in the regenerative research literature. It has been studied for more than fifty years, it occurs naturally in human plasma, and its mechanism is unusually well characterised for a compound of its size.

This page sets out what GHK-Cu is chemically, how the copper coordination works, what the published research has actually reported, and — just as importantly — where the evidence stops.

All material on this site is supplied strictly for in vitro laboratory research. Nothing here is guidance for use in humans or animals.

In short

• GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, bound 1:1
• First isolated from human plasma in 1973; circulating levels decline with age
• The copper is not incidental — the complex acts as a copper shuttle, and much of the reported activity is copper-dependent
• Reported to increase collagen, elastin and glycosaminoglycan synthesis in fibroblast and wound models
• Connectivity Map analysis reports transcriptional changes across roughly a third of human genes — a screening signal, not a demonstrated outcome
• The literature is overwhelmingly preclinical, and no human efficacy has been established for systemic use

Quick reference

What GHK-Cu is

GHK is a tripeptide: three amino acids — glycine, histidine and lysine — joined in sequence. On its own it is a small, unremarkable-looking molecule. What makes it interesting is its affinity for copper(II) ions, which it binds in a 1:1 complex to form GHK-Cu.

The peptide was first isolated from human plasma in 1973 by Loren Pickart, working on why albumin fractions from younger donors caused older liver tissue to behave more like younger tissue in culture. The active factor turned out to be GHK. Pickart proposed that it worked by chelating metal ions, and by 1980 the group had published in Nature on the idea that the peptide functions by facilitating copper uptake into cells.

GHK is also present in saliva and urine, and is thought to be liberated from larger extracellular proteins by proteolysis during tissue injury. Reported plasma concentrations decline with age — figures of roughly 200 ng/mL at age 20 falling to around 80 ng/mL by age 60 are widely cited. That age-related decline is what motivated most of the subsequent research on exogenous GHK-Cu.

Why the copper matters

It is easy to read “copper peptide” as a peptide that happens to contain copper. The chemistry is more specific than that.

The imidazole nitrogen of the histidine residue, the N-terminal amine and the peptide backbone nitrogen together form a coordination site with high affinity for Cu(II). The resulting complex is stable enough to survive in circulation but labile enough to exchange copper with other cellular ligands — which is the property that lets it behave as a copper shuttle rather than a copper sink.

Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for superoxide dismutase, tyrosinase and several other enzymes. Free copper ions, by contrast, are cytotoxic and catalyse damaging Fenton chemistry. A molecule that can deliver copper in a controlled, bioavailable form without releasing free ionic copper is therefore doing something the free ion cannot.

This is why the research literature treats the intact GHK-Cu complex and the free GHK peptide as related but distinct entities. Much of the reported activity is copper-dependent.

Reported mechanisms of action

Extracellular matrix synthesis

In fibroblast culture and in animal wound models, GHK-Cu has been reported to increase mRNA production for collagen, elastin, proteoglycans and glycosaminoglycans, and to stimulate synthesis of decorin — a small proteoglycan involved in regulating collagen fibril assembly.

Some studies report collagen synthesis increases on the order of tens of percent relative to untreated controls, though the magnitude varies considerably with cell passage number, culture conditions and which collagen subtype is being measured. Effect sizes in this literature should be read with that variability in mind.

Protease modulation

GHK-Cu has been reported to modulate the balance between matrix metalloproteinases (MMPs), which degrade extracellular matrix, and their tissue inhibitors (TIMPs). The proposed picture is not simple upregulation of matrix production but a shift in the remodelling balance — increasing synthesis while restraining excessive breakdown.

Antioxidant and anti-inflammatory activity

Reported antioxidant actions include blocking formation of reactive oxygen and carbonyl species, and detoxifying products of lipid peroxidation such as acrolein. GHK has also been reported to suppress signalling through NF-κB, a transcription factor central to inflammatory responses.

Angiogenesis and nerve outgrowth

In model systems, GHK-Cu has been reported to stimulate blood vessel formation and nerve outgrowth — both processes relevant to how tissue repair is studied in vitro.

The gene expression data

The most-cited finding on GHK-Cu, and the one most often misrepresented, concerns gene expression.

Using the Broad Institute’s Connectivity Map — a database that profiles how cell lines respond transcriptionally to different compounds — Pickart and colleagues reported that GHK produced a change of 50% or greater in the expression of approximately 31% of human genes. Depending on which paper in the series you read, the figure is given as 31.2% or 32.1%; both refer to the same underlying analysis.

Two things are worth being precise about here.

First, this is a transcriptional signature in cultured cell lines, not a demonstration of physiological effect in an organism. Connectivity Map data is a screening and hypothesis-generating tool. A 50% change in transcript level is a low threshold, and a signature is not an outcome.

Second, the more interesting result is arguably narrower. Hong and colleagues, working on emphysema, identified a gene expression signature associated with emphysematous lung destruction and used the Connectivity Map to search for compounds that would reverse it. GHK came up. When they treated human fibroblasts with GHK, the cells recapitulated TGFβ-induced expression patterns, showed organisation of the actin cytoskeleton, and elevated integrin β1 expression. That is a specific, testable, independently motivated result — and it arrived at GHK from the disease end rather than from the peptide end, which makes it harder to dismiss.

Related analyses have reported directional patterns in DNA repair gene expression, and gene resetting in cancer and COPD cell models toward expression patterns characteristic of healthier tissue.

Where the evidence stops

Any honest reference on GHK-Cu has to be clear about the limits, and there are three worth stating plainly.

Most of the literature is preclinical. The body of work is largely in vitro, in cell culture, and in animal models. Topical cosmetic formulations have been studied in people, but that is a different route, a different dose and a different endpoint from the systemic effects often attributed to the compound in online discussion.

A large share of the foundational literature comes from one group. Loren Pickart discovered GHK, authored or co-authored a substantial proportion of the review literature, and has had commercial interests in copper peptide products. That does not invalidate the work — the Nature paper and the independent emphysema study stand on their own — but a research reference should note where concentration of authorship exists rather than presenting fifty years of one group’s reviews as fifty years of independent replication.

Gene expression breadth is not the same as therapeutic breadth. The “modulates 4,000 genes” figure circulates widely as though it were evidence of potency. Broad transcriptional activity is as easily read as low specificity. It is a reason to investigate, not a conclusion.

No efficacy in humans has been established for the systemic applications discussed in the preclinical literature, and GHK-Cu holds no marketing authorisation as a medicine in the UK.

Handling and storage

For laboratory use, GHK-Cu is typically supplied as a lyophilised powder. General handling practice reported in the literature:

• Store sealed vials at -20°C, protected from light and moisture
• Allow vials to reach room temperature before opening to avoid condensation
• The complex is light-sensitive; minimise exposure during handling
• Copper complexes can be displaced by competing chelators — check buffer compatibility before assay design
• Solution stability is lower than lyophilised stability; prepare working solutions close to point of use

All handling, reconstitution and experimental procedures are determined by the receiving laboratory under its own protocols and risk assessments.

Verifying what you have

Purity claims on research peptides are only as good as the documentation behind them.

For GHK-Cu specifically, look for:

• HPLC purity trace with the batch number visible
• Mass spectrometry confirming the expected mass for the copper complex, not just the free peptide
• Copper content confirmation — an uncomplexed GHK peptide is a different compound
• A batch-specific certificate, not a generic specimen document

Our GHK-Cu 50mg is supplied with batch documentation, and current testing status for any compound is available on request via our COA archive.

References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(124):85-87.
2. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288:715-717.
3. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988.
4. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxidative Medicine and Cellular Longevity. 2012;2012:324832.
5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International. 2014;2014:151479.
6. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67.
7. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.

GHK-Cu is supplied by Premium Lab Peptides strictly for in vitro laboratory research. It is not a licensed medicine, is not for human or veterinary consumption, and no guidance on human use is provided or implied. Premium Lab Peptides is a trading name of Invicta Alliance Limited.